U.S. FDA approves AstraZeneca diabetes drug for treating heart failure risk
Share:
(Reuters) - AstraZeneca's diabetes drug Farxiga has been approved for use in the United States as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks, the British drugmaker said on Monday.The approval by the U.S. Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial, the London-listed company said, and follows a similar approval..